Safety and Pharmacokinetics of Motesanib in Combination With Panitumumab and Gemcitabine-Cisplatin in Patients With Advanced Cancer

Journal of Oncology - United States
doi 10.1155/2011/853931
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Hindawi Limited

Related search

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Randomized Phase 2 Study of Gemcitabine and Cisplatin With or Without Vitamin Supplementation in Patients With Advanced Esophagogastric Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination With Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2007English

Comparison of the Efficacy Between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2014English

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination With Chemotherapy in Asian Patients With Advanced Solid Tumors: Phase Ib Study

Targeted Oncology
Cancer ResearchOncologyPharmacology
2020English

Binimetinib Plus Gemcitabine and Cisplatin Phase I/Ii Trial in Patients With Advanced Biliary Cancers

Clinical Cancer Research
Cancer ResearchOncology
2019English

A Phase I/Ii Study of LY900003, an Antisense Inhibitor of Protein Kinase C- , in Combination With Cisplatin and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy